Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made
tremendous progress with five CAR T therapies approved by the US Food and Drug …

Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

Cell-membrane-coated nanoparticles are widely studied due to their inherent cellular
properties, such as immune escape and homologous homing. A cell membrane coating can …

The past decade has witnessed ongoing progress in immune therapy to ameliorate human
health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the …

Epithelial–mesenchymal transition (EMT) has been shown to play a critical role in tumor
development from initiation to metastasis. EMT could be regarded as a continuum, with …

As a promising alternative platform for cellular immunotherapy, natural killer cells (NK) have
recently gained attention as an important type of innate immune regulatory cell. NK cells can …

Although chimeric antigen receptor (CAR)-engineered T cells have shown great success in
the treatment of B cell malignancies, this strategy has limited efficacy in patients with solid …

Chimeric antigen receptor T (CAR-T) cell therapy achieved extraordinary achievements
results in antitumor treatments, especially against hematological malignancies, where it …

Complex interactions between the immune system and tumor cells exist throughout the
initiation and development of cancer. Although the immune system eliminates malignantly …

Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …